Asterias Biotherapeutics Inc (NYSE:AST) received a $12.00 target price from HC Wainwright in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 287.10% from the stock’s current price.

Separately, Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, July 17th.

Asterias Biotherapeutics (NYSE:AST) opened at 3.10 on Wednesday. The company’s market capitalization is $152.72 million. The company’s 50-day moving average is $3.45 and its 200 day moving average is $3.41. Asterias Biotherapeutics has a one year low of $2.54 and a one year high of $5.80.

Asterias Biotherapeutics (NYSE:AST) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.25 million. Asterias Biotherapeutics had a negative net margin of 312.79% and a negative return on equity of 58.31%. Analysts predict that Asterias Biotherapeutics will post ($0.68) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/asterias-biotherapeutics-inc-ast-given-a-12-00-price-target-at-hc-wainwright/1492751.html.

A number of large investors have recently made changes to their positions in the company. California State Teachers Retirement System increased its stake in shares of Asterias Biotherapeutics by 4.6% in the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,100 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock worth $206,000 after buying an additional 6,714 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Asterias Biotherapeutics by 24.1% in the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 63,773 shares during the last quarter.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.